Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics (NASDAQ: SNSE) announced progress in its clinical programs, including pre-IND feedback from the FDA for SNS-101, an anti-VISTA antibody, expected to file an IND in the first half of 2023. The company will present new pharmacokinetic data in non-human primates in Q3 2022. The strong financial position, with cash equivalents of $123.7 million, supports operations through Q1 2025. Research and development expenses increased to $6.4 million due to higher headcount and inflation. The net loss was reported at $10.5 million for Q2 2022.
On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.
Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.
Sensei Biotherapeutics (SNSE) reported Q1 2022 financial results, highlighting a net loss of $12.4 million, up from $8.0 million in Q1 2021. The company's cash reserves stood at $136.2 million, sufficient to fund operations through Q1 2025. Progress on the TMAb™ platform includes promising preclinical data for SNS-101, an anti-VISTA antibody targeting solid tumors, which showed selective binding in low pH environments. The firm also anticipates submitting an IND for SNS-101 in the first half of 2023 following successful GMP manufacturing initiation.
Sensei Biotherapeutics (NASDAQ: SNSE) announced significant advancements in its pipeline with the initiation of new therapeutic programs, including SNS-101, an anti-VISTA antibody. The company reported a strong cash position of $147.6 million as of December 31, 2021, providing a runway into the first half of 2024. Additionally, the management team was strengthened with key appointments. SNS-101 shows promise against the VISTA immune checkpoint, vital for overcoming challenges in cancer treatment.
Sensei Biotherapeutics (NASDAQ: SNSE) has appointed William Ringo as chair of its Board of Directors, enhancing leadership during a pivotal phase for the company. Ringo, with over 40 years in the pharmaceutical and biotech industries, brings extensive experience from Pfizer and Eli Lilly. His leadership is expected to support Sensei's objectives in developing innovative cancer therapies, particularly through its unique TMAb™ and ImmunoPhage™ platforms. The company is focused on advancing treatments such as SNS-101 and SNS-401-NG.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Company leaders, including John Celebi and Erin Colgan, will present virtually on March 15 at 10:40 am ET. A replay of the presentation will be available for 90 days on their website. Sensei Biotherapeutics focuses on developing next-generation cancer immunotherapies, utilizing its innovative TMAb and ImmunoPhage platforms for personalized treatment options.
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in Citi's 2022 Immuno-Oncology Summit. Dr. Robert Pierce, Chief R&D Officer, will engage in a fireside chat on February 16, 2022, at 2:30 PM ET. The event will be webcast live, with a replay available for 90 days on the company's website. Sensei Biotherapeutics specializes in next-generation immunotherapies for cancer, utilizing its TMAb™ platform for antibody development and ImmunoPhage™ platform to create personalized treatments for various cancers.
Sensei Biotherapeutics has announced key promotions within its leadership team, appointing Erin Colgan as Chief Financial Officer and Robert Pierce, M.D. as Chief Research & Development Officer. Colgan, previously Senior VP of Finance, brings extensive experience from Intarcia Therapeutics and Vertex Pharmaceuticals. Dr. Pierce, who has over 20 years in scientific leadership, shifted from Chief Scientific Officer, enhancing his role to include drug discovery and clinical development. CEO John Celebi expressed confidence in their capabilities to drive the company’s future growth.
Summary not available.